Mitchell, J., Camacho, N., Shea, P., Stopsack, K. H., Joseph, V., Burren, O. S., Dhindsa, R. S., Nag, A., Berchuck, J. E., O’Neill, A., Abbasi, A., Zoghbi, A. W., Alegre-Díaz, J., Kuri-Morales, P., Berumen, J., Tapia-Conyer, R., Emberson, J., Torres, J. M., Collins, R., … Fabre, M. A. (2025). Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-56944-1

Aparicio, L., Crowley, L., Christin, J. R., Laplaca, C. J., Hibshoosh, H., Rabadan, R., & Shen, M. M. (2025). Meta-analyses of mouse and human prostate single-cell transcriptomes reveal widespread epithelial plasticity in tissue regression, regeneration, and cancer. Genome Medicine, 17(1). https://doi.org/10.1186/s13073-025-01432-w

Chesner, L. N., Polesso, F., Graff, J. N., Hawley, J. E., Smith, A. K., Lundberg, A., Das, R., Shenoy, T., Sjöström, M., Zhao, F., Hu, Y.-M., Linder, S., Chen, W. S., Hawkins, R. M., Shrestha, R., Zhu, X., Foye, A., Li, H., Kim, L. M., … Moran, A. E. (2024). Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer. Cancer Discovery, 15(3), 481–494. https://doi.org/10.1158/2159-8290.cd-24-0559

De Felice, D., Alaimo, A., Bressan, D., Genovesi, S., Marmocchi, E., Annesi, N., Beccaceci, G., Dalfovo, D., Cutrupi, F., Medaglia, S., Foletto, V., Lorenzoni, M., Gandolfi, F., Kannan, S., Verma, C. S., Vasciaveo, A., Shen, M. M., Romanel, A., Chiacchiera, F., … Lunardi, A. (2024). Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer. EMBO Reports. https://doi.org/10.1038/s44319-024-00335-y

Mejia, E., Lewis, A. G. C., Garcés-Palacio, I. C., Hernandez, D. M., Chamberlain, R. M., & Soliman, A. S. (2024). Relationship between universal health insurance benefits and prostate cancer mortality in Colombia. BMC Public Health, 24(1). https://doi.org/10.1186/s12889-024-20117-4

Dallos, M. C., Obradovic, A. Z., McCann, P., Chowdhury, N., Pratapa, A., Aggen, D. H., Gaffney, C., Autio, K. A., Virk, R. K., De Marzo, A. M., Antonarakis, E. S., Scher, H. I., Drake, C. G., & Rathkopf, D. E. (2024). Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. Clinical Cancer Research, 30(22), 5218–5230. https://doi.org/10.1158/1078-0432.ccr-24-0060

Lopez-Bujanda, Z. A., Hadavi, S. H., Ruiz De Porras, V., Martínez-Balibrea, E., & Dallos, M. C. (2024). Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets. Chemokine Receptors in Health and Disease, 162–205. https://doi.org/10.1016/bs.ircmb.2024.03.008

Quintanal-Villalonga, A., Kawasaki, K., Redin, E., Uddin, F., Rakhade, S., Durani, V., Sabet, A., Shafer, M., Karthaus, W. R., Zaidi, S., Zhan, Y. A., Manoj, P., Sridhar, H., Kinyua, D., Zhong, H., Mello, B. P., Ciampricotti, M., Bhanot, U. K., Linkov, I., … Rudin, C. M. (2024). CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01908-y

Mao, J., Genkinger, J. M., Rundle, A. G., Wright, J. D., Insaf, T. Z., Schymura, M. J., Hu, J. C., & Tehranifar, P. (2024). Racial and ethnic disparities in robot-assisted radical prostatectomy: testing the physician-level segregated and differential treatment hypotheses. JNCI Cancer Spectrum, 8(4). https://doi.org/10.1093/jncics/pkae061

Papachristodoulou, A., Heidegger, I., Virk, R. K., Di Bernardo, M., Kim, J. Y., Laplaca, C., Picech, F., Schäfer, G., De Castro, G. J., Hibshoosh, H., Loda, M., Klocker, H., Rubin, M. A., Zheng, T., Benson, M. C., McKiernan, J. M., Dutta, A., & Abate-Shen, C. (2024). Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. European Urology, 85(4), 361–372. https://doi.org/10.1016/j.eururo.2023.07.016

Yuan, H., Kehm, R. D., Daaboul, J. M., Lloyd, S. E., McDonald, J. A., Mu, L., Tehranifar, P., Zhang, K., Terry, M. B., & Yang, W. (2024). Cancer incidence trends in New York State and associations with common population-level exposures 2010–2018: an ecological study. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-56634-w

Yu, J. B., DeStephano, D. M., Jeffers, B., Horowitz, D. P., Soulos, P. R., Gross, C. P., & Cheng, S. K. (2024). Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal of Clinical Oncology, 42(16), 1943–1952. https://doi.org/10.1200/jco.23.01604

Sadasivan, S. M., Loveless, I. M., Chen, Y., Gupta, N. S., Sanii, R., Bobbitt, K. R., Chitale, D. A., Williamson, S. R., Rundle, A. G., & Rybicki, B. A. (2024). Patterns of B‐cell lymphocyte expression changes in pre‐ and post‐malignant prostate tissue are associated with prostate cancer progression. Cancer Medicine, 13(6). Portico. https://doi.org/10.1002/cam4.7118

Pakula, H., Omar, M., Carelli, R., Pederzoli, F., Fanelli, G. N., Pannellini, T., Socciarelli, F., Van Emmenis, L., Rodrigues, S., Fidalgo-Ribeiro, C., Nuzzo, P. V., Brady, N. J., Dinalankara, W., Jere, M., Valencia, I., Saladino, C., Stone, J., Unkenholz, C., Garner, R., … Loda, M. (2024). Distinct mesenchymal cell states mediate prostate cancer progression. Nature Communications, 15(1). https://doi.org/10.1038/s41467-023-44210-1

Galván, G. C., Macias, E., Sanders, S., Ramirez-Torres, A., Stock, S., You, S., Riera, C. E., Tamukong, P., Smith-Warner, S. A., Genkinger, J. M., Luthringer, D. J., Freeman, M. R., & Freedland, S. J. (2023). The effects of glycemic index on prostate cancer progression in a xenograft mouse model. Prostate Cancer and Prostatic Diseases, 27(2), 348–354. https://doi.org/10.1038/s41391-023-00769-w

Gaynor, A. M., Flaherty, K. R., Root, J. C., Salas-Ramirez, K. Y., Scott, J. M., & Nelson, C. J. (2023). Exercise Associated with Cognitive Function in Older Men with Prostate Cancer Undergoing Androgen Deprivation Therapy. International Journal of Behavioral Medicine, 30(6), 924–929. https://doi.org/10.1007/s12529-022-10150-1

Ribault, A., Benadjaoud, M. A., Squiban, C., Arnaud, L., Judicone, C., Leroyer, A. S., Rousseau, A., Huet, C., Guha, C., Benderitter, M., Lacroix, R., Flamant, S., Chen, E. I., Simon, J.-M., & Tamarat, R. (2023). Circulating microvesicles correlate with radiation proctitis complication after radiotherapy. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-022-21726-y

Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006

Mao, J., Genkinger, J. M., Rundle, A. G., Wright, J. D., Schymura, M. J., Insaf, T. Z., Hu, J. C., & Tehranifar, P. (2023). Robot-Assisted Surgery and Racial and Ethnic Disparities in Post-Prostatectomy Outcomes Among Prostate Cancer Patients. Annals of Surgical Oncology, 31(2), 1373–1383. https://doi.org/10.1245/s10434-023-14447-7

Guner, L. A., Unal, K., Beylergil, V., Tuna, M. B., Saglican, Y., Vardareli, E., & Kural, A. R. (2023). Enhancing PSMA PET/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma. Annals of Nuclear Medicine, 37(11), 618–628. https://doi.org/10.1007/s12149-023-01864-7

Camargo, J. A., Viana, N. I., Pimenta, R., Guimarães, V. R., dos Santos, G. A., Candido, P., Ghazarian, V., Romão, P., Silva, I. A., Birbrair, A., Srougi, M., Nahas, W. C., Leite, K. R., Trarbach, E. B., & Reis, S. T. (2023). The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer. International Journal of Molecular Sciences, 24(19), 14847. https://doi.org/10.3390/ijms241914847

Chestang, J., Wang, S., & Yu, J. B. (2023). Prostate cancer in New York City: impact of neighborhood level social determinants of care. Prostate Cancer and Prostatic Diseases, 26(3), 628–630. https://doi.org/10.1038/s41391-023-00687-x

Madan, R. A., Bilusic, M., Stein, M. N., Donahue, R. N., Arlen, P. M., Karzai, F., Plimack, E., Wong, Y.-N., Geynisman, D. M., Zibelman, M., Mayer, T., Strauss, J., Chen, G., Rauckhorst, M., McMahon, S., Couvillon, A., Steinberg, S., Figg, W. D., Dahut, W. L., … Gulley, J. L. (2023). Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The Oncologist, 28(7), 642-e561. https://doi.org/10.1093/oncolo/oyad058

Dickstein, D. R., Edwards, C. R., Lehrer, E. J., Tarras, E. S., Gallitto, M., Sfakianos, J., Galsky, M. D., Stock, R., Safer, J. D., Rosser, B. R. S., & Marshall, D. C. (2023). Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. Nature Reviews Urology, 20(6), 332–355. https://doi.org/10.1038/s41585-023-00778-3

Tshering, L. F., Luo, F., Russ, S., Szenk, M., Rubel, D., Tutuska, K., Rail, J. G., Balázsi, G., Shen, M. M., & Talos, F. (2023). Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Developmental Cell, 58(12), 1071-1086.e8. https://doi.org/10.1016/j.devcel.2023.04.010

Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., Ward, J. F., Tidwell, R. S. S., Troncoso, P., Corn, P. G., Logothetis, C. J., Knoblauch, R., Hutnick, N., Gottardis, M., Drake, C. G., … Subudhi, S. K. (2023). Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for ImmunoTherapy of Cancer, 11(3), e006262. https://doi.org/10.1136/jitc-2022-006262

Horn, D., Sacarny, A., & Zhou, A. (2022). Technology adoption and market allocation: The case of robotic surgery. Journal of Health Economics, 86, 102672. https://doi.org/10.1016/j.jhealeco.2022.102672

Mapanga, W., Norris, S. A., Craig, A., Pumpalova, Y., Ayeni, O. A., Chen, W. C., Jacobson, J. S., Neugut, A. I., Muchengeti, M., Pentz, A., Doherty, S., Minkowitz, S., Haffejee, M., Rebbeck, T., & Joffe, M. (2022). Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa. PLOS ONE, 17(10), e0276050. https://doi.org/10.1371/journal.pone.0276050

Kim, M. S., Naidoo, D., Hazra, U., Quiver, M. H., Chen, W. C., Simonti, C. N., Kachambwa, P., Harlemon, M., Agalliu, I., Baichoo, S., Fernandez, P., Hsing, A. W., Jalloh, M., Gueye, S. M., Niang, L., Diop, H., Ndoye, M., Snyper, N. Y., Adusei, B., … Lachance, J. (2022). Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biology, 23(1). https://doi.org/10.1186/s13059-022-02766-z

Movassaghi, M., Ahmed, F., Patel, H., Luk, L., Hyams, E., Wenske, S., & Shaish, H. (2022). Association of Patient and Imaging-Related Factors With False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions. Urology, 167, 165–170. https://doi.org/10.1016/j.urology.2022.04.026

Papachristodoulou, A., & Abate-Shen, C. (2022). Precision intervention for prostate cancer: Re-evaluating who is at risk. Cancer Letters, 538, 215709. https://doi.org/10.1016/j.canlet.2022.215709

Patel, H., Ahmed, F., Luk, L., Navot, B., & Shaish, H. (2022). Impact of enema prep on the false-negative rate of a PI-RADS 1 MRI of the prostate for clinically significant prostate cancer. Abdominal Radiology, 47(7), 2494–2499. https://doi.org/10.1007/s00261-022-03547-9

Shah, N. J., Patel, V. G., Zhong, X., Pina, L., Hawley, J. E., Lin, E., Gartrell, B. A., Febles, V. A., Wise, D. R., Qin, Q., Mellgard, G., Joshi, H., Nauseef, J. T., Green, D. A., Vlachostergios, P. J., Kwon, D. H., Huang, F., Liaw, B., Tagawa, S., … Oh, W. K. (2022). The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum, 6(3). https://doi.org/10.1093/jncics/pkac035

Abate-Shen, C., & Nunes de Almeida, F. (2022). Establishment of the LNCaP Cell Line – The Dawn of an Era for Prostate Cancer Research. Cancer Research, 82(9), 1689–1691. https://doi.org/10.1158/0008-5472.can-22-1065

Rybicki, B. A., Sadasivan, S. M., Chen, Y., Loveless, I., Gupta, N. S., Chitale, D. A., Williamson, S. R., Rundle, A. G., & Tang, D. L. (2022). Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention, 31(5), 991–998. https://doi.org/10.1158/1055-9965.epi-21-1221

Lopez-Bujanda, Z. A., Haffner, M. C., Chaimowitz, M. G., Chowdhury, N., Venturini, N. J., Patel, R. A., Obradovic, A., Hansen, C. S., Jacków, J., Maynard, J. P., Sfanos, K. S., Abate-Shen, C., Bieberich, C. J., Hurley, P. J., Selby, M. J., Korman, A. J., Christiano, A. M., De Marzo, A. M., & Drake, C. G. (2021). Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nature Cancer, 2(8), 803–818. https://doi.org/10.1038/s43018-021-00227-3

Vogl, U. M., Beer, T. M., Davis, I. D., Shore, N. D., Sweeney, C. J., Ost, P., Attard, G., Bossi, A., de Bono, J., Drake, C. G., Efstathiou, E., Fanti, S., Fizazi, K., Halabi, S., James, N., Mottet, N., Padhani, A. R., Roach, M., Rubin, M., … Gillessen, S. (2022). Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 160, 24–60. https://doi.org/10.1016/j.ejca.2021.09.036